The Technology

The core of the Company's technology is built around a  unique recombinant human lactoferrin (rhLTF), a molecule having mammalian  glycosylation. To our knowledge, this is the only rhLTF that is fully  compatible with humans and currently available for preclinical testing. A  novel fusion protein of hLTF with the Fc domain of IgG represents a  natural extension of the Company’s portfolio of products for future clinical  utility.